Welcome, OmniSeq customers
In 2021 Labcorp welcomed OmniSeq, its customers, employees, testing portfolio and services to the Labcorp family.
How OmniSeq expands the Labcorp Oncology portfolio
Clinical Testing
OmniSeq INSIGHT® is a comprehensive genomic and immune profiling assay for all solid tumors. How to order this test.
Research Services
The OmniSeq lab offers expanded capacity for contract research services like genomic and immune profiling, gene expression, TCRβ repertoire and PDL-1 IHC, transcriptome sequencing and genome / exome sequencing.
Quick links
Contact Us
Our customer support team is still ready to answer your questions and help you.
Review Lab Certifications
Download CLIA and other certifications for our lab in New York.
Log into the OmniSeq portal
Use the portal to check results, adjust orders and track a specimen status.
Are you a patient or caregiver?
Call 800-781-1259 us for billing or financial assistance.
Explore more resources for patients
Publications and posters
The OmniSeq legacy
Roswell Park Comprehensive Cancer Center in Buffalo, New York is a pioneer clinical research facility for advanced treatment of all forms of adult and pediatric cancer, and a Member of the National Comprehensive Cancer Network. Roswell Park Comprehensive Cancer Center’s Founder, Dr. Roswell Park, sought to cure cancer and advocated a close connection between laboratory and clinical research to speed up discovery, and Roswell Park Comprehensive Cancer Center was the first institution to focus exclusively on cancer research.
After more than a century, Roswell Park Comprehensive Cancer Center continues to be at the forefront of groundbreaking cancer research. The institute’s history includes initiating the first experiments in chemotherapy in 1904; becoming America’s first Comprehensive Cancer Center; and providing the source, RP11 (RP stands for Roswell Park), for much of the BAC clone library used in the Human Genome Project.
OmniSeq® emerged from the Roswell Park Comprehensive Cancer Center’s Center of Personalized Medicine in 2015.
In 2021, Labcorp acquired OmniSeq® to better serve patients needing a tissue-based sequencing test for late-stage solid tumors.